Dear Investors,
Frenelle is developing next-generation long-acting injectable therapeutics using its proprietary Faros™ drug-delivery platform. Its lead program, FRN01, is a 30-day subcutaneous buprenorphine injection being developed for Opioid Use Disorder.
Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing to learn more about Frenelle’s technology, development progress, and investment opportunity.
Why Investors Are Taking Notice
Large, Underpenetrated Market — The global long-acting injectable buprenorphine market exceeded $1.2B in 2025, yet remains underpenetrated.
Differentiated Approach — FRN01 is designed to deliver monthly treatment while addressing key patient and access barriers.
Promising Development Progress — FRN01 has demonstrated formulation proof of concept and encouraging PK and toxicology results.
Experienced Team & Platform — Frenelle combines pharmaceutical development expertise with Mayo Clinic collaboration and a platform with broader therapeutic potential.
